[Back to Issue 11 ToC] [Back to Journal Contents] [Back to Biochemistry (Moscow) Home page]
[View Full Article] [Download Reprint (PDF)]

REVIEW: Myeloid-Derived Suppressor Cells and Proinflammatory Cytokines as Targets for Cancer Therapy

K.-S. N. Atretkhany1,2 and M. S. Drutskaya1,2*

1Engelhardt Institute of Molecular Biology, 119991 Moscow, Russia; E-mail: marinadru@gmail.com

2Lomonosov Moscow State University, Biological Faculty, 119991 Moscow, Russia

* To whom correspondence should be addressed.

Received July 5, 2016; Revision received July 9, 2016
Myeloid-derived suppressor cells represent a heterogeneous population of immature myeloid cells. Under normal conditions, these cells differentiate into macrophages, dendritic cells, and granulocytes. However, in pathological states such as inflammation, infection, or tumor growth, there is an arrest of their differentiation that results in the accumulation of immature myeloid cells in the organism. In addition, these cells acquire a suppressor phenotype, expressing anti-inflammatory cytokines and reactive oxygen and nitrogen species, and suppress T-cell immune response. Myeloid-derived suppressor cells (MDSC) contribute to cancerogenesis by forming a favorable microenvironment for tumor growth. Proinflammatory cytokines, secreted by tumor cells and the tumor microenvironment, induce angiogenesis and metastasis and promote tumor growth. They also provide signals necessary for survival, accumulation, and function of MDSC. Understanding the mechanisms of myeloid suppressor cell development and the use of proinflammatory cytokine inhibitors may prove beneficial for tumor therapy.
KEY WORDS: MDSC, TNF, IL-6, IL-1, tumor microenvironment, tumor-associated inflammation

DOI: 10.1134/S0006297916110055